Syndax announces fda approval of revuforj® (revumenib), the first and only menin inhibitor to treat adult and pediatric patients with relapsed or refractory acute leukemia with a kmt2a translocation

– approval based on positive data from the augment-101 clinical trial, in which revuforj delivered robust and durable rates of remission in r/r acute leukemia patients with a kmt2a translocation – – syndax to host conference call today at 6:00 p.m. et – waltham, mass.
KMT Ratings Summary
KMT Quant Ranking